Intravenous thrombolysis with recombinant tissue plasminogen activator (rtPA) is an effective treatment for acute ischaemic stroke, although its use for patients with mild forms of this condition remains controversial. Here, Guerrero and Savitz outline the potential risks and benefits of rtPA in this patient population, and explain why they believe patients with mild ischaemic stroke should receive this treatment.
- Waldo R. Guerrero
- Sean I. Savitz
